GlassScriptPhysician profile
Monika Akula
NPI 1154783678
$4,042.35
in general payments reported to CMS, 2019-2025
29 companies · $864 in 2025
The $864 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184 · 2020: $60.91 · 2021: $143 · 2022: $574 · 2023: $1,268 · 2024: $948 · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,981 · Gift: $99.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,980.59 |
| Gift | $99.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $817.75 | 2020-2025 | Ozempic, Rybelsus, Sogroya |
| Mannkind Corporation | $551.62 | 2022-2024 | Afrezza |
| Lilly USA, LLC | $443.10 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $285.01 | 2022-2025 | |
| Amgen INC. | $224.17 | 2021-2025 | Evenity, Prolia, Tepezza |
| Medtronic, INC. | $177.86 | 2021-2024 | Minimed 780g |
| Medtronic Minimed, INC. | $171.44 | 2019-2020 | |
| Abbott Laboratories | $156.91 | 2022-2023 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $140.19 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Pfizer INC. | $138.65 | 2024-2025 | |
| Abbvie INC. | $137.02 | 2019-2025 | Synthroid |
| Amneal Pharmaceuticals LLC | $125.66 | 2024-2025 | Unithroid |
| Recordati_rare_diseases_inc. | $95.06 | 2025 | Isturisa |
| Embecta Corp. | $68.82 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Alexion Pharmaceuticals, INC. | $65.01 | 2020-2025 | Strensiq |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.53 | 2019-2024 | Jardiance |
| Radius Health, INC. | $49.83 | 2023-2024 | |
| Becton, Dickinson and Company | $43.33 | 2022 | |
| Ibsa Pharma INC. | $43.30 | 2021-2024 | Tirosint, Licart |
| Chiesi USA, INC. | $39.09 | 2025 | Mycapssa |
| Bayer Healthcare Pharmaceuticals INC. | $35.33 | 2024 | |
| Ascendis Pharma Endocrinology INC | $31.72 | 2023-2025 | Yorvipath |
| Astrazeneca Pharmaceuticals LP | $29.38 | 2021-2024 | Farxiga |
| Madrigal Pharmaceuticals | $28.59 | 2025 | Rezdiffra |
| Insulet Corporation | $21.41 | 2025 | Omnipod |
| Ardelyx, INC. | $19.73 | 2025 | Ibsrela |
| Almatica Pharma LLC | $16.56 | 2024 | Teriparatide |
| Paratek Pharmaceuticals, INC. | $14.50 | 2021 | |
| Amphastar Pharmaceuticals, INC. | $13.78 | 2023 | Baqsimi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monika Akula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.